CY2404B1 - Use of rapamycin derivatives in vasculopathies andxenotransplantation. - Google Patents

Use of rapamycin derivatives in vasculopathies andxenotransplantation.

Info

Publication number: CY2404B1
Authority: CY; Cyprus
Prior art keywords: andxenotransplantation; vasculopathies; rapamycin derivatives; rapamycin; deoxyspergualine
Prior art date: 1996-03-27

Application number

CY0400004A

Other languages

English (en)

Inventor

Walter Schuler

Hendrik Schuurman

Gisbert Weckbecker

Hans-Guenter Zerwes

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-27

Filing date

2004-01-08

Publication date

2004-09-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10791127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2404(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-01-08 Application filed by Novartis Ag filed Critical Novartis Ag

2004-09-10 Publication of CY2404B1 publication Critical patent/CY2404B1/xx

Links

QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
229930105110 Cyclosporin A Natural products 0.000 abstract 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
108010036949 Cyclosporine Proteins 0.000 abstract 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 abstract 1
208000024248 Vascular System injury Diseases 0.000 abstract 1
208000012339 Vascular injury Diseases 0.000 abstract 1
206010053648 Vascular occlusion Diseases 0.000 abstract 1
229960002170 azathioprine Drugs 0.000 abstract 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 abstract 1
229960001265 ciclosporin Drugs 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
210000000265 leukocyte Anatomy 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
229960000485 methotrexate Drugs 0.000 abstract 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 abstract 1
RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 abstract 1
229960004866 mycophenolate mofetil Drugs 0.000 abstract 1
229960000951 mycophenolic acid Drugs 0.000 abstract 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1
229960002930 sirolimus Drugs 0.000 abstract 1
229960001967 tacrolimus Drugs 0.000 abstract 1
230000008719 thickening Effects 0.000 abstract 1
208000021331 vascular occlusion disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Saccharide Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CY0400004A 1996-03-27 2004-01-08 Use of rapamycin derivatives in vasculopathies andxenotransplantation. CY2404B1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9606452.2A GB9606452D0 (en)	1996-03-27	1996-03-27	Organic compounds

Publications (1)

Publication Number	Publication Date
CY2404B1 true CY2404B1 (en)	2004-09-10

Family

ID=10791127

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CY0400004A CY2404B1 (en)	1996-03-27	2004-01-08	Use of rapamycin derivatives in vasculopathies andxenotransplantation.

Country Status (29)

Country	Link
US (5)	US6384046B1 (xx)
EP (3)	EP0893996B1 (xx)
JP (2)	JP2000507226A (xx)
KR (2)	KR100836971B1 (xx)
CN (1)	CN1124135C (xx)
AT (1)	ATE224194T1 (xx)
AU (1)	AU716514B2 (xx)
BR (1)	BR9708358A (xx)
CA (1)	CA2247275C (xx)
CY (1)	CY2404B1 (xx)
CZ (1)	CZ292483B6 (xx)
DE (1)	DE69715611T2 (xx)
DK (2)	DK2008657T3 (xx)
ES (2)	ES2421455T3 (xx)
GB (1)	GB9606452D0 (xx)
HU (1)	HU226422B1 (xx)
ID (1)	ID17195A (xx)
IL (1)	IL125812A (xx)
MY (1)	MY117798A (xx)
NO (1)	NO316667B1 (xx)
NZ (1)	NZ331463A (xx)
PL (1)	PL187732B1 (xx)
PT (2)	PT893996E (xx)
RU (1)	RU2214247C2 (xx)
SI (1)	SI2008657T1 (xx)
SK (1)	SK284343B6 (xx)
TR (1)	TR199801919T2 (xx)
WO (1)	WO1997035575A1 (xx)
ZA (1)	ZA972719B (xx)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9606452D0 (en) *	1996-03-27	1996-06-05	Sandoz Ltd	Organic compounds
ES2182112T3 (es)	1996-07-30	2003-03-01	Novartis Ag	Composiciones farmaceuticas para el tratamiento del rechazo de transplantes y de estados autoinmunes o inflamatorios, que comprenden ciclosporina a y 40-o-(2-hidroxietil)-rapamicina.
US6890546B2 (en)	1998-09-24	2005-05-10	Abbott Laboratories	Medical devices containing rapamycin analogs
US20030129215A1 (en) *	1998-09-24	2003-07-10	T-Ram, Inc.	Medical devices containing rapamycin analogs
JP2002544167A (ja) *	1999-05-10	2002-12-24	ノバルティスアクチエンゲゼルシャフト	有機化合物
US6790228B2 (en)	1999-12-23	2004-09-14	Advanced Cardiovascular Systems, Inc.	Coating for implantable devices and a method of forming the same
US20070032853A1 (en)	2002-03-27	2007-02-08	Hossainy Syed F	40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7807211B2 (en)	1999-09-03	2010-10-05	Advanced Cardiovascular Systems, Inc.	Thermal treatment of an implantable medical device
US8088060B2 (en)	2000-03-15	2012-01-03	Orbusneich Medical, Inc.	Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20030229393A1 (en) *	2001-03-15	2003-12-11	Kutryk Michael J. B.	Medical device with coating that promotes cell adherence and differentiation
US9522217B2 (en)	2000-03-15	2016-12-20	Orbusneich Medical, Inc.	Medical device with coating for capturing genetically-altered cells and methods for using same
US20070141107A1 (en) *	2000-03-15	2007-06-21	Orbusneich Medical, Inc.	Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US20070055367A1 (en) *	2000-03-15	2007-03-08	Orbus Medical Technologies, Inc.	Medical device with coating that promotes endothelial cell adherence and differentiation
US8460367B2 (en) *	2000-03-15	2013-06-11	Orbusneich Medical, Inc.	Progenitor endothelial cell capturing with a drug eluting implantable medical device
DE60128451T2 (de)	2000-03-15	2007-08-30	OrbusNeich Medical, Inc., Fort Lauderdale	Beschichtung welche ein anhaften von endothelzellen stimuliert
US8236048B2 (en)	2000-05-12	2012-08-07	Cordis Corporation	Drug/drug delivery systems for the prevention and treatment of vascular disease
US20050002986A1 (en) *	2000-05-12	2005-01-06	Robert Falotico	Drug/drug delivery systems for the prevention and treatment of vascular disease
US7300662B2 (en)	2000-05-12	2007-11-27	Cordis Corporation	Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020013335A1 (en) *	2000-06-16	2002-01-31	American Home Products Corporation	Method of treating cardiovascular disease
EP1709974A3 (en) *	2000-06-16	2006-12-06	Wyeth	Method of treating cardiovascular disease using rapamycin
US6670355B2 (en) *	2000-06-16	2003-12-30	Wyeth	Method of treating cardiovascular disease
JP5100951B2 (ja)	2000-09-29	2012-12-19	コーディス・コーポレイション	被覆医用器具
CZ307940B6 (cs)	2001-02-19	2019-09-04	Novartis Pharma Ag	40-O-(2-hydroxyethyl)rapamycin pro použití při léčení
US8741378B1 (en)	2001-06-27	2014-06-03	Advanced Cardiovascular Systems, Inc.	Methods of coating an implantable device
US6939376B2 (en)	2001-11-05	2005-09-06	Sun Biomedical, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
US7682387B2 (en) *	2002-04-24	2010-03-23	Biosensors International Group, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
AP2004003113A0 (en) *	2002-02-22	2004-09-30	Prophy Med Ab	Use of an inhibitor or antagonist against tissue factor
US20040024450A1 (en) *	2002-04-24	2004-02-05	Sun Biomedical, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
AU2003241515A1 (en) *	2002-05-20	2003-12-12	Orbus Medical Technologies Inc.	Drug eluting implantable medical device
US8109987B2 (en)	2003-04-14	2012-02-07	Tryton Medical, Inc.	Method of treating a lumenal bifurcation
US7279174B2 (en)	2003-05-08	2007-10-09	Advanced Cardiovascular Systems, Inc.	Stent coatings comprising hydrophilic additives
US20050118344A1 (en)	2003-12-01	2005-06-02	Pacetti Stephen D.	Temperature controlled crimping
US7220755B2 (en) *	2003-11-12	2007-05-22	Biosensors International Group, Ltd.	42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US9114198B2 (en)	2003-11-19	2015-08-25	Advanced Cardiovascular Systems, Inc.	Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
WO2005107817A2 (en) *	2004-04-30	2005-11-17	Orbus Medical Technologies, Inc.	Medical device with coating for capturing genetically-altered cells and methods of using same
US20110104186A1 (en)	2004-06-24	2011-05-05	Nicholas Valiante	Small molecule immunopotentiators and assays for their detection
US8709469B2 (en)	2004-06-30	2014-04-29	Abbott Cardiovascular Systems Inc.	Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7901451B2 (en) *	2004-09-24	2011-03-08	Biosensors International Group, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
WO2006069038A1 (en) *	2004-12-20	2006-06-29	Ariad Gene Therapeutics, Inc.	Therapeutic materials and methods
US20070185150A1 (en)	2005-11-14	2007-08-09	Bedrosian Camille L	Therapeutic methods
US20080317814A1 (en) *	2005-11-17	2008-12-25	Access Plus Co., Ltd.	Tube for Connecting Marteriovenous and Interposition for Medical Operation
US20070173923A1 (en) *	2006-01-20	2007-07-26	Savage Douglas R	Drug reservoir stent
CN104906087A (zh)	2006-09-13	2015-09-16	万能医药公司	大环内酯化合物及它们的使用方法
US20080097591A1 (en)	2006-10-20	2008-04-24	Biosensors International Group	Drug-delivery endovascular stent and method of use
US8067055B2 (en) *	2006-10-20	2011-11-29	Biosensors International Group, Ltd.	Drug-delivery endovascular stent and method of use
US20080103584A1 (en)	2006-10-25	2008-05-01	Biosensors International Group	Temporal Intraluminal Stent, Methods of Making and Using
KR100930167B1 (ko) *	2007-09-19	2009-12-07	삼성전기주식회사	초광각 광학계
US8661630B2 (en)	2008-05-21	2014-03-04	Abbott Cardiovascular Systems Inc.	Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
US8573150B2 (en)	2007-11-14	2013-11-05	Biosensors International Group, Ltd.	Automated stent coating apparatus and method
EP2245165A4 (en) *	2008-01-11	2011-06-01	Massachusetts Eye & Ear Infirm	TRANSGENIC CONDITIONAL STOP DIMERICABLE CASPASE ANIMALS
KR20110074758A (ko) *	2008-10-03	2011-07-01	엘릭서 메디컬 코포레이션	마크로사이클릭 락톤 화합물 및 이를 사용하는 방법
US8382818B2 (en)	2009-07-02	2013-02-26	Tryton Medical, Inc.	Ostium support for treating vascular bifurcations
US8685433B2 (en)	2010-03-31	2014-04-01	Abbott Cardiovascular Systems Inc.	Absorbable coating for implantable device
UA104738C2 (ru)	2011-05-18	2014-03-11	Олег Миколайович Лазаренко	Композиция для повышения биосовместимости имплантатов и клеток для трансплантации с организмом реципиента и способ ее приготовления
CN102268015B (zh) *	2011-08-30	2013-08-28	成都摩尔生物医药有限公司	一种依维莫司的合成方法
US10682415B2 (en)	2013-07-22	2020-06-16	Wisconsin Alumni Research Foundation	Thermogel formulation for combination drug delivery
KR101723265B1 (ko)	2013-08-16	2017-04-04	가톨릭대학교 산학협력단	mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
EP3049020B1 (en)	2013-09-24	2022-06-15	Giner Life Sciences, Inc.	System for gas treatment of a cell implant
JP6529012B2 (ja)	2013-10-08	2019-06-12	エイアイ・セラピューティクス・インコーポレーテッド	リンパ脈管筋腫症の処置のためのラパマイシン
US10307371B2 (en)	2014-02-11	2019-06-04	AI Therapeutics, Inc.	Rapamycin for the treatment of lymphangioleiomyomatosis
CN106573067A (zh)	2014-02-11	2017-04-19	拉姆医疗公司	用于淋巴管平滑肌瘤病治疗的雷帕霉素
MX394266B (es)	2014-04-04	2025-03-24	Ai Therapeutics Inc	Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
BR112017006842A2 (pt)	2014-10-07	2017-12-12	Lam Therapeutics Inc	formulação de rapamicina inalável para o tratamento de hipertensão pulmonar
MA40910A (fr)	2014-11-07	2017-09-12	Civitas Therapeutics Inc	Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en)	2015-02-10	2016-08-18	Lam Therapeutics, Inc.	Rapamycin for the treatment of lymphangioleiomyomatosis
BR112019002689A2 (pt)	2016-08-10	2019-05-14	Univ Texas	terapia com rapamicina tópica
US20190388210A1 (en)	2016-09-19	2019-12-26	Biotronik Ag	Polymer-Free Drug Eluting Vascular Stents
KR20190086489A (ko)	2016-11-15	2019-07-22	기너 라이프 사이언시즈, 인크.	피하 임플란트와 함께 이용하기에 적합한 경피 가스 확산 장치
WO2018114989A1 (en)	2016-12-22	2018-06-28	Biotronik Ag	Intratumoral drug delivery materials and methods for treating breast cancer
US11642501B2 (en)	2017-05-04	2023-05-09	Giner, Inc.	Robust, implantable gas delivery device and methods, systems and devices including same
UY37900A (es)	2017-09-26	2019-04-30	Novartis Ag	Nuevos derivados de rapamicina
WO2020128861A1 (en)	2018-12-18	2020-06-25	Novartis Ag	Rapamycin derivatives
MX2021010058A (es)	2019-02-20	2021-11-12	Ai Therapeutics Inc	Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5639724A (en) *	1984-07-24	1997-06-17	Sandoz Ltd.	Cyclosporin galenic forms
US5364612A (en) *	1991-05-06	1994-11-15	Immunomedics, Inc.	Detection of cardiovascular lesions
ZA924953B (en) *	1991-07-25	1993-04-28	Univ Louisville Res Found	Method of treating ocular inflammation
CA2086642C (en) *	1992-01-09	2004-06-15	Randall E. Morris	Method of treating hyperproliferative vascular disease
US5516781A (en) *	1992-01-09	1996-05-14	American Home Products Corporation	Method of treating restenosis with rapamycin
KR100284210B1 (ko) *	1992-04-28	2001-03-02	이건 이. 버그	과증식성 혈관 질환 치료용 배합 제제
US5747034A (en) *	1992-07-09	1998-05-05	Chiron Corporation	Methods and materials for the induction of T cell anergy
US5283257A (en) *	1992-07-10	1994-02-01	The Board Of Trustees Of The Leland Stanford Junior University	Method of treating hyperproliferative vascular disease
GB9221220D0 (en) *	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
ES2146741T3 (es) *	1993-12-17	2000-08-16	Novartis Ag	Derivados de rapamicina utiles como inmunosupresores.
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US6265427B1 (en) *	1995-06-07	2001-07-24	The Proctor & Gamble Company	Pharmaceutical composition for the method of treating leukemia
KR100400620B1 (ko) *	1995-06-09	2004-02-18	노파르티스 아게	라파마이신유도체
GB9606452D0 (en) *	1996-03-27	1996-06-05	Sandoz Ltd	Organic compounds

1996
- 1996-03-27 GB GBGB9606452.2A patent/GB9606452D0/en active Pending
1997
- 1997-03-25 ID IDP970980A patent/ID17195A/id unknown
- 1997-03-25 MY MYPI97001258A patent/MY117798A/en unknown
- 1997-03-26 AT AT97915441T patent/ATE224194T1/de not_active IP Right Cessation
- 1997-03-26 ES ES08017336T patent/ES2421455T3/es not_active Expired - Lifetime
- 1997-03-26 CA CA2247275A patent/CA2247275C/en not_active Expired - Lifetime
- 1997-03-26 IL IL12581297A patent/IL125812A/en not_active IP Right Cessation
- 1997-03-26 TR TR1998/01919T patent/TR199801919T2/xx unknown
- 1997-03-26 HU HU0001267A patent/HU226422B1/hu unknown
- 1997-03-26 ES ES97915441T patent/ES2184078T3/es not_active Expired - Lifetime
- 1997-03-26 DK DK08017336.2T patent/DK2008657T3/da active
- 1997-03-26 RU RU98119312/14A patent/RU2214247C2/ru active
- 1997-03-26 PL PL97328659A patent/PL187732B1/pl unknown
- 1997-03-26 PT PT97915441T patent/PT893996E/pt unknown
- 1997-03-26 BR BR9708358A patent/BR9708358A/pt not_active Application Discontinuation
- 1997-03-26 CN CN97193278A patent/CN1124135C/zh not_active Expired - Lifetime
- 1997-03-26 NZ NZ331463A patent/NZ331463A/en not_active IP Right Cessation
- 1997-03-26 EP EP97915441A patent/EP0893996B1/en not_active Revoked
- 1997-03-26 AU AU22918/97A patent/AU716514B2/en not_active Expired
- 1997-03-26 EP EP01116262A patent/EP1149581A3/en not_active Withdrawn
- 1997-03-26 CZ CZ19983070A patent/CZ292483B6/cs not_active IP Right Cessation
- 1997-03-26 WO PCT/EP1997/001548 patent/WO1997035575A1/en not_active Application Discontinuation
- 1997-03-26 KR KR1020057005463A patent/KR100836971B1/ko not_active Expired - Lifetime
- 1997-03-26 DE DE69715611T patent/DE69715611T2/de not_active Revoked
- 1997-03-26 DK DK97915441T patent/DK0893996T3/da active
- 1997-03-26 SK SK1327-98A patent/SK284343B6/sk not_active IP Right Cessation
- 1997-03-26 PT PT80173362T patent/PT2008657E/pt unknown
- 1997-03-26 EP EP08017336.2A patent/EP2008657B1/en not_active Expired - Lifetime
- 1997-03-26 KR KR1020077008212A patent/KR20070083654A/ko not_active Withdrawn
- 1997-03-26 JP JP9532077A patent/JP2000507226A/ja not_active Withdrawn
- 1997-03-26 SI SI9730801T patent/SI2008657T1/sl unknown
- 1997-03-27 ZA ZA972719A patent/ZA972719B/xx unknown
1998
- 1998-09-18 NO NO19984340A patent/NO316667B1/no not_active IP Right Cessation
2000
- 2000-11-14 US US09/712,359 patent/US6384046B1/en not_active Expired - Lifetime
2002
- 2002-03-07 US US10/092,639 patent/US20020127248A1/en not_active Abandoned
2004
- 2004-01-08 CY CY0400004A patent/CY2404B1/xx unknown
2008
- 2008-12-10 JP JP2008314494A patent/JP5124431B2/ja not_active Expired - Lifetime
2010
- 2010-03-01 US US12/715,007 patent/US20100152105A1/en not_active Abandoned
2012
- 2012-01-24 US US13/357,199 patent/US20120177690A1/en not_active Abandoned
2014
- 2014-03-05 US US14/197,368 patent/US20140187574A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NZ331463A (en)	2001-10-26
ES2421455T3 (es)	2013-09-02
PT893996E (pt)	2002-12-31
PL187732B1 (pl)	2004-09-30
CZ307098A3 (cs)	1999-01-13
IL125812A (en)	2001-12-23
KR20070083654A (ko)	2007-08-24
NO316667B1 (no)	2004-03-29
NO984340L (no)	1998-09-18
CA2247275A1 (en)	1997-10-02
JP2009102349A (ja)	2009-05-14
CA2247275C (en)	2011-10-11
CN1214631A (zh)	1999-04-21
JP2000507226A (ja)	2000-06-13
RU2214247C2 (ru)	2003-10-20
IL125812A0 (en)	1999-04-11
TR199801919T2 (xx)	1999-02-22
WO1997035575A1 (en)	1997-10-02
US20020127248A1 (en)	2002-09-12
EP2008657A3 (en)	2009-02-04
ID17195A (id)	1997-12-11
AU716514B2 (en)	2000-02-24
US20100152105A1 (en)	2010-06-17
EP2008657B1 (en)	2013-04-24
DK2008657T3 (da)	2013-07-22
BR9708358A (pt)	1999-08-03
EP1149581A2 (en)	2001-10-31
CZ292483B6 (cs)	2003-09-17
ATE224194T1 (de)	2002-10-15
DE69715611T2 (de)	2003-05-22
CN1124135C (zh)	2003-10-15
EP2008657A2 (en)	2008-12-31
SI2008657T1 (sl)	2013-07-31
KR20050038656A (ko)	2005-04-27
HUP0001267A2 (hu)	2000-11-28
PL328659A1 (en)	1999-02-15
MY117798A (en)	2004-08-30
PT2008657E (pt)	2013-07-12
EP0893996A1 (en)	1999-02-03
GB9606452D0 (en)	1996-06-05
HK1018688A1 (en)	1999-12-30
NO984340D0 (no)	1998-09-18
SK132798A3 (en)	1999-03-12
US20140187574A1 (en)	2014-07-03
US6384046B1 (en)	2002-05-07
DE69715611D1 (de)	2002-10-24
US20120177690A1 (en)	2012-07-12
EP0893996B1 (en)	2002-09-18
HU226422B1 (en)	2008-12-29
HUP0001267A3 (en)	2002-01-28
ZA972719B (en)	1998-09-28
SK284343B6 (sk)	2005-02-04
JP5124431B2 (ja)	2013-01-23
KR100836971B1 (ko)	2008-06-10
EP1149581A3 (en)	2003-12-03
DK0893996T3 (da)	2002-12-09
AU2291897A (en)	1997-10-17
ES2184078T3 (es)	2003-04-01

Publication	Publication Date	Title
CY2404B1 (en)	2004-09-10	Use of rapamycin derivatives in vasculopathies andxenotransplantation.
EA200000848A1 (ru)	2001-04-23	Способ селективного снижения числа или активности макрофагов (варианты), способ лечения или профилактики заболевания субъекта (варианты), способ диагностики заболевания у субъекта
IL140137A (en)	2005-03-20	Receptor bodies specifically binding tie-2 ligands
TW249198B (en)	1995-06-11	Stents for autologous tissue heart valve
ZA951292B (en)	1996-08-16	4-amino derivatives of mycophenolic acid
ES2054627T3 (es)	1994-08-16	Indolinas 3,3-disustituidas.
ES2184800T3 (es)	2003-04-16	Uso de agentes anti-vegf en el tratamiento de la endometriosis.
WO2001082899A3 (en)	2002-06-13	Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
FI963101A7 (fi)	1996-08-06	Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoo n, joissa seerumin interleukiini-6-taso on kohonnut
DE69121608D1 (de)	1996-10-02	Verfahren zur Vorsulfidierung von Hydrobehandlungs-, Hydrokrackung- oder Restgasbehandlungskatalysatoren
WO2003101919A3 (en)	2004-07-22	Scorpionate-like pendant macrocyclic ligands, complexes and compositions thereof, and methods of using same
RU98101907A (ru)	1999-11-10	Терапевтические агенты и аутоимунные заболевания
DE69522564D1 (de)	2001-10-11	Alkalibeständiges proteinadsorbens
RU96118929A (ru)	1998-12-10	Способ повышения защитных свойств организма при воздействии внешних физических факторов
DE602004017838D1 (de)	2009-01-02	Verfahren zur herstellung von 6-ä(4,5-dihydro-1h-imidazol-2-yl)amino-ü-7-methyl-1h-benzimidazol-4-carbonitrile und dessen bevorzugte salzform
DK0745071T3 (da)	2002-04-02	4-Amino-6-substitueret mycophenolsyre og derivater med immunsuppressiv virkning
IL112666A0 (en)	1995-05-26	4-amino derivatives of 5-substituted mycophenolic acid, their preparation and pharmaceutical compositions containing them
RU2000124058A (ru)	2002-08-10	Способ лечения миопии
RU96119633A (ru)	1998-12-20	Способ лечения аметропий и разницы в функциональных показателях правого и левого глаза по святковской т.я.
Pioli	1993	Reactivation failure in infants: A processing analysis.
UA36539A (uk)	2001-04-16	Спосіб проведення тренувань, що засновані на переміщеннях пацієнта, та комплекс засобів для його здійснення
RU97113539A (ru)	1999-08-10	Способ лечения заболеваний, вызываемых микроорганизмами